Global Huntington's Disease Market - 2023-2030
Global Huntington's Disease Market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2030 growing with a CAGR of XX% during the forecast period 2023-2030.
Huntington's disease is an inherited disease that causes the degeneration of nerve cells in the central nervous system (CNS). The disease has a broad impact on the functional abilities of humans and usually results in movement and thinking disabilities. Most people with Huntington's disease develop signs and symptoms in the age of 30 to 40.
When the disease begins before age 20, the condition is known as juvenile Huntington's disease. Both men and women are susceptible to this disease. It is an inherited neurodegenerative disorder characterized by a combination of motor, cognitive, and psychiatric symptoms.
Increasing Pipeline Drugs
Extensive pipeline drugs with properties such as high patient compliance and improved safety also support the growth of the global Huntington's disease therapeutics market. For instance, according to Huntington's Disease Society of America, UniQure is developing AMT-130, a genetic drug designed to silence the huntingtin mutant protein. PTC Therapeutics has also developed an oral splice modulator called PTC518, which reduces huntingtin levels.
Sage Therapeutics is working on Sage-718, an NMDA receptor antagonist that completed an early safety trial in individuals with Huntington's disease.
Annexon Biosciences is developing ANX-005, an antibody given by IV that aims to help preserve the connections between neurons (synapses) in the HD brain. SRX246, an investigational drug to treat symptoms of anxiety and aggression in the early stages of HD, was invented by Azevan Pharmaceuticals. These Drugs are currently in the pipeline, tested extensively, and later released into the market after approval.
Furthermore, the rise in demand for advanced disease treatment, increasing awareness about chronic diseases, new drug discoveries are few factors that drive the market in the forthcoming period.
Termination of Clinical Trials
Currently, only two drugs were approved, Tetrabenazine and deutetrabenazine, for treating chorea. Other than these, there are no approved drugs until now, although several companies worked on the development. For instance, Novartis initially developed Branaplam, an oral drug to treat a childhood disorder called spinal muscular atrophy. It was also found to lower huntington protein by interfering with the genetic recipe in a process known as RNA splicing. Unfortunately, a Phase 2 trial in adults with HD was halted in 2022 for safety reasons after branaplam unexpectedly caused nerve damage.Segment Analysis
The global Huntington’s disease market is segmented based on drug class, distribution channel, and region.
The Deutetrabenazine Drug/Therapy Segment Accounted for Approximately XX% of the Market Share
Xenazine (tetrabenazine) and Austedo (deutetrabenazine) are two antidopaminergic medications approved by the U. S. Food and Drug Administration (FDA) to treat symptoms of chorea in Huntington’s disease. They work by blocking VMAT proteins and dopamine receptors. Austedo’s chemical structure is similar to Xenazine, but it is more stable.
According to an article published in Bionews,Inc. in January 2022, the proportion of patients with an adherence rate of AUSTEDO (Deutrabenazine) refill is higher i.e., 78% compared to Xenazine (tetrabenazine) i.e., 69% was observed in a group of patient population.
Additionally, On October 2022, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. released the results from the ARC-HD (Alternatives for Reducing Chorea in Huntington’s Disease) trial, an approximately 3-year open-label, single-arm, 2-cohort, multicenter extension study evaluating the safety and tolerability of long-term treatment with AUSTEDO (deutetrabenazine) tablets for chorea associated with Huntington’s Disease (HD).Geographical Analysis
North America accounted for Approximately XX% of the Market Share in 2022
North America is expected to hold the largest segment due to the drug pipeline, the prevalence of Huntington’s disease, and increasing clinical trials.
For instance, according to the Journal of Neurology Research 2022 issue, the worldwide prevalence is extensively varied with an equal distribution between men and women. It is estimated in 5-10 cases per 100,000 inhabitants. Annual incidence varies between one and four cases per million inhabitants.
Additionally, in December 2022, Sage Therapeutics, California, United States is conducting phase 3 clinical trial to evaluate the safety and tolerability of SAGE-718 soft gel lipid capsule in participants with Huntington's Disease (HD)
COVID-19 Impact Analysis
The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting drug development activities worldwide. The COVID-19 pandemic severely disrupted global supply chains, affecting the transportation of raw materials to pharmaceutical manufacturing industries.
The focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. This diversion of resources and attention may have temporarily impacted the progress of disease-related research and development activities. This has led to delays in the completion of trials and the availability of new therapies, which has affected the market.
By Drug Class
• Antipsychotic drugs
• Psychotropic medication
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• North America
Rest of Europe
• South America
Rest of South America
Rest of Asia-Pacific
• Middle East and AfricaCompetitive Landscape
The major global players in the Huntington's disease market include Teva Pharmaceuticals, Apotex Corporation, Pfizer, Rosemont Pharma, Agnito Pharma, Merck & Co, Eli Lilly Company, Ralington Pharma, Par Pharmaceutical, and Accord Healthcare among others.Key Developments
• On July 2023, Lupin Inc., based in Somerset, New Jersey, U.S received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Chlorpromazine Hydrochloride Tablets.
• In Jan 2022, Ionis Pharmaceuticals, Inc. launched the designing of a phase 2 trial by their partner Roche to assess Tominersen in Huntington’s disease.Why Purchase the Report?
• To visualize the global Huntington's disease market segmentation based on drug class, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of Huntington's disease market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global Huntington’s disease market report would provide approximately 53 tables, 54 figures, and 195 Pages.Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies